Janus Henderson Group PLC Purchases 576,059 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Janus Henderson Group PLC boosted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 15.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,339,254 shares of the company’s stock after acquiring an additional 576,059 shares during the period. Janus Henderson Group PLC owned approximately 0.13% of Lexeo Therapeutics worth $28,508,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LXEO. Barclays PLC increased its stake in Lexeo Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after acquiring an additional 31,057 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after purchasing an additional 5,915 shares during the period. SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $72,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $46,000. Finally, Rhumbline Advisers grew its stake in shares of Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock valued at $166,000 after purchasing an additional 4,127 shares during the period. 60.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on LXEO. Leerink Partners lowered their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Chardan Capital lowered their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. Royal Bank of Canada lowered their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $21.80.

Lexeo Therapeutics Stock Down 4.9%

NASDAQ LXEO opened at $2.69 on Thursday. The firm has a market cap of $89.30 million, a PE ratio of -0.85 and a beta of 1.27. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $19.50. The stock’s 50 day simple moving average is $3.06 and its 200 day simple moving average is $5.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19). As a group, sell-side analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.